ReviewArchives of dermatological research2019
The role of adipokines in systemic sclerosis: a missing link?
Review in Archives of dermatological research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications.Archives of dermatological research · 2021Trial
- Reprogramming of the lipid metabolism axis in systemic sclerosis: mechanism analysis and therapeutic potential.Clinical rheumatology · 2026Review
- Temporal Dissociation of Impaired Glucose Tolerance, Adipose Lipid Remodeling and Endothelial Dysfunction in Aorta After HFD Withdrawal.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- A Cross-Sectional Study: Systematic Quantification of Chemerin in Human Cerebrospinal Fluid.Biomedicines · 2024Article
- Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review.Clinical rheumatology · 2024Review
- Gut microbiome and metabolomics in systemic sclerosis: feature, link and mechanisms.Frontiers in immunology · 2024Review
- In the Pursuit of Metabolic Markers of Systemic Sclerosis-Plasma Adiponectin and Omentin-1 in Monitoring the Course of the Disease.International journal of molecular sciences · 2023Article
- Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review.International journal of molecular sciences · 2023Review
- Keloid Core Factor CTRP3 Overexpression Significantly Controlled TGF-Disease markers · 2023Article
- Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.Journal of inflammation research · 2023Review
- Sympatho-Vagal Dysfunction in Systemic Sclerosis: A Follow-Up Study.Life (Basel, Switzerland) · 2022Article
- The Effect of Body Fat Distribution on Systemic Sclerosis.Journal of clinical medicine · 2022Article
- Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis.Clinical and experimental medicine · 2022Article
- The Systolic Pulmonary Arterial Pressure Liaises Impaired Cardiac Autonomic Control to Pro-inflammatory Status in Systemic Sclerosis Patients.Frontiers in cardiovascular medicine · 2022Article
- Intimate intertwining of the pathogenesis of hypoxia and systemic sclerosis: A transcriptome integration analysis.Frontiers in immunology · 2022Article
- Body mass index and adipokines/cytokines dysregulation in systemic sclerosis.Clinical and experimental immunology · 2021Article
- Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis.Clinical rheumatology · 2021Article
- Adiponectin as a novel biomarker of disease severity in alopecia areata.Scientific reports · 2021Article
- Adipose-derived stem cells: Pathophysiologic implicationsWorld journal of stem cells · 2021Review
- Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis.Postepy dermatologii i alergologii · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis is a multiorgan autoimmune disease characterized by vasculopathy and tissue fibrosis of unknown etiology. Recently, adipokines (cell signaling proteins secreted by adipose tissue) have attracted much attention as a cytokine family contributing to the various pathological processes of systemic sclerosis. Adipokines, such as leptin, adiponectin, resistin, adipsin, visfatin or chemerin are a heterogenic group of molecules. Adiponectin exhibits anti-fibrotic features and affects inflammatory reactions. Leptin promotes fibrosis and inflammation. Resistin was linked to vascular involvement in systemic sclerosis. Visfatin was associated with regression of skin lesions in late-stage systemic sclerosis. Chemerin appears as a marker of increased risk of impaired renal function and development of skin sclerosis in the early stage of systemic sclerosis. Vaspin was indicated to have a protective role in digital ulcers development. Novel adipokines-adipsin, apelin, omentin and CTRP-3-are emerging as molecules potentially involved in SSc pathogenesis. Serum adipokine levels may be used as predictive and diagnostic factors in systemic sclerosis. However, further investigations are required to establish firm correlations between distinct adipokines and systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.